Join our dynamic team at Cytodigm, where innovation meets opportunity! As a preclinical-stage biopharmaceutical company founded in 2022, we are at the forefront of developing next-generation therapeutics. Our proprietary platforms, Cytofinity™ and Sigfinity™, offer groundbreaking approaches to enhancing targetability and delivery efficiency while minimizing immunogenicity and toxicity. We are also harnessing the power of our clinically proven Zetafinity® polymer nanoparticles to tackle solid tumors.

At Cytodigm, we are committed to advancing our technology to clinical proof of concept and collaborating with leading biopharmaceutical partners to maximize platform value. If you are passionate about making a difference in cell, gene, and immune therapy and eager to grow with a company dedicated to pioneering therapeutic advancements, we encourage you to apply and join us on this exciting journey.